早期HER2阳性乳腺癌辅助帕妥珠单抗联合曲妥珠单抗和化疗的6年绝对无侵袭性疾病生存获益:APHINITY(BIG 4-11)试验的亚群治疗效应模式图(STEPP)分析
本研究为APHINITY试验的STEPP探索性分析,评估在曲妥珠单抗联合化疗基础上加用帕妥珠单抗对早期HER2阳性乳腺癌6年无侵袭性疾病生存率的绝对差异。结果显示总体6年IDFS绝对获益为2.8±0.9%,淋巴结阳性(N+)为4.5±1.2%,淋巴结阴性(N-)为0.1±1.1%。N-亚组未识别出明确获益亚群,N+亚组未识别出需降阶梯治疗亚群。
要点
- 总体6年IDFS绝对获益为2.8±0.9%,N+为4.5±1.2%,N-为0.1±1.1%。
- N-亚组STEPP图未识别出明确从加用帕妥珠单抗获益的亚群。
- N+亚组STEPP图未识别出需降阶梯治疗的亚群;TILs百分比似乎比临床复合风险评分更能预测帕妥珠单抗疗效。
核心结论
- N-亚组的STEPP图未识别出明确从加用帕妥珠单抗获益的亚群,N+亚组的STEPP图未识别出需降阶梯治疗的亚群。
- TILs百分比似乎比临床复合风险评分更能预测帕妥珠单抗的治疗效应。
研究设计与样本
- 本研究为APHINITY(BIG 4-11)试验的STEPP探索性分析,STEPP是一种探索性图形方法,针对由感兴趣协变量定义的重叠患者亚群绘制治疗效应估计值。
- 研究使用STEPP估计6年IDFS百分比差异(帕妥珠单抗组减安慰剂组:Δ±标准误[SE]),分别按总体及淋巴结状态,在由以下协变量定义的重叠亚群中进行分析:(1)临床复合风险评分,(2)肿瘤浸润淋巴细胞(TILs)百分比,(3)人表皮生长因子受体2(HER2)FISH拷贝数。
- 由于多重性,Δ至少达到3个SE才值得关注。
主要发现
- 6年IDFS百分比的平均绝对获益:总体为2.8±0.9%;N+为4.5±1.2%;N-为0.1±1.1%。
- 获益最大的亚群包括:中等临床复合风险患者(总体5.3±1.9%;N+ 6.9±2.3%;N- 4.0±3.0%);最高TILs百分比患者(总体6.3±1.7%;N+ 7.4±2.4%;N- 3.2±1.7%);中等HER2拷贝数患者(总体2.8±1.9%;N+ 7.4±2.5%;N- -1.3±1.9%)。
- 但缺乏明确证据表明存在亚群治疗效应差异的模式。
局限性
- 由于多重性,Δ至少达到3个SE才值得关注。
- 缺乏明确证据表明存在亚群治疗效应差异的模式。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: The APHINITY trial showed that adding adjuvant pertuzumab (P) to trastuzumab and chemotherapy, compared with adding placebo (Pla), significantly improved invasive disease-free survival (IDFS) for patients with HER2+ early breast cancer both overall and for the node-positive (N+) cohort. We explored whether adding P could benefit some N- subpopulations and whether to consider de-escalation for some N+ subpopulations. METHODS: Subpopulation Treatment Effect Pattern Plot (STEPP) is an exploratory, graphical method that plots estimates of treatment effect for overlapping patient subpopulations defined by a covariate of interest. We used STEPP to estimate Kaplan-Meier differences in 6-year IDFS percentages (P minus Pla: Δ ± standard error [SE]), both overall and by nodal status, for overlapping subpopulations defined by (1) a clinical composite risk score, (2) tumour infiltrating lymphocytes (TILs) percentage, and (3) human epidermal growth factor receptor 2 (HER2) FISH copy number. Because of multiplicity, a Δ of at least three SE is required to warrant attention. RESULTS: The average absolute gains in 6-year IDFS percentages were 2.8 ± 0.9 overall; 4.5 ± 1.2 for N+ and 0.1 ± 1.1 for N-. Largest gains were for patients with intermediate clinical composite risk (5.3 ± 1.9 overall; 6.9 ± 2.3 N+; 4.0 ± 3.0 N-), highest TILs percentage (6.3 ± 1.7 overall; 7.4 ± 2.4 N+; 3.2 ± 1.7 N-), and intermediate HER2 copy number (2.8 ± 1.9 overall; 7.4 ± 2.5 N+; -1.3 ± 1.9 N-), but clear evidence indicating a pattern of differential subpopulation treatment effects was lacking. CONCLUSIONS: STEPP plots for N- did not identify subpopulations clearly benefiting from adding P, and those for N+ did not identify subpopulations warranting de-escalation. TILs percentage appeared to be more predictive of P treatment effect than clinical composite risk score. TRIAL REGISTRATION: clinicaltrials.gov Identifier NCT01358877.
引用
- Gelber RD, Wang XV, Cole BF, et al. Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial. Eur J Cancer. 2022. PMID: 35313167. doi:10.1016/j.ejca.2022.01.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。